Soluble Guanylyl Cyclase (sGC) in Mechanisms of Hypotensive and Antiaggregatory Effects Induced by Teraphtal (TP, sodium salt 4,5-cardoxyphtalocyanin-cobalt)
Open Access
- 1 April 2016
- journal article
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 9 (2)
Abstract
Background & Aims. Many antitumor drugs produces not only the variety of therapeutic effects but also a broad spectrum of side effects, including acute hemodynamic dysfunctions (hypotension/hypertension, coagulation disorders). The aim of the paper is to investigate the role of soluble guanylyl cyclase (sGC) in mechanisms of hypotensive and antiaggregatory effects induced by teraphtal (TP) under experimental conditions in the clinic. Methods. The effect of different products on the basal activity of sGC isolated from platelets of human peripheral blood was assessed by the immunoenzyme method based on production of cyclic guanosine monophosphate (cGMP). The effect of TP on ADP-induced human platelet aggregation was evaluated by the turbidimetric Born method using an aggregometer. Results. In the presence of TP, the basal sGC activity increased by the average of 2.5-fold. The TF-induced dose-response curve of sGC activation displays a bell-shaped behavior with maximal stimulation effect achieved at a concentration of 1 mmol/L. TP does not affect the sGC activation induced by known sGC regulators, such as sodium nitroprusside (SNP) and YC-1. On the other hand, after preliminary incubation of sGC with TP, the ability of YC-1 to potentiate the enzyme stimulation induced by SNP decreased by about 33 %. In vitro tests demonstrated the ability of TP to inhibit the ADP-induced platelet aggregation and established the IC50 value for TP (15 mmol/L). Conclusion. TF is a direct sGC activator and therefore is able to participate in regulation of the NO®sGC®cGMP signaling pathway that controls the basal vascular tone and aggregatory platelet properties. Taking into account the TP characteristics, the paper discusses the involvement of additional mechanisms in the development of hypotension and hemostatic disorders induced by the drug.Keywords
This publication has 65 references indexed in Scilit:
- Phenylephrine activates eNOS Ser1177 phosphorylation and nitric oxide signaling in renal hypertensive rat aortaEuropean Journal of Pharmacology, 2014
- Risk factors for developing oral 5-aminolevulenic acid-induced side effects in patients undergoing fluorescence guided resectionPhotodiagnosis and Photodynamic Therapy, 2013
- Sunitinib, Hypertension, and Heart Failure: A Model for Kinase Inhibitor-Mediated CardiotoxicityCurrent Hypertension Reports, 2011
- Cardiovascular effects of systemic cancer treatmentCancer Treatment Reviews, 2011
- Mechanisms of Antiangiogenic-Induced Arterial HypertensionCurrent Hypertension Reports, 2011
- The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthaseArchives of Pharmacal Research, 2010
- Cardiovascular Complications of Cancer TherapyJACC, 2009
- Versatile pharmacological actions of YC-1: anti-platelet to anticancerCancer Letters, 2004
- Immune-mediated side-effects of cytokines in humansToxicology, 1995
- Orthostatic Hypotension During Vincristine TherapyArchives of internal medicine (1960), 1970